{"id":"W2803252171","doi":"10.2146/ajhp170707","title":"Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events","year":2018,"lang":"en","type":"review","venue":"American Journal of Health-System Pharmacy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"","keywords":"Evolocumab; Alirocumab; PCSK9; Kexin; Medicine; Proprotein convertase; Pharmacology; Placebo; Adverse effect; Familial hypercholesterolemia; Internal medicine; Cholesterol; LDL receptor; Lipoprotein","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000451797,0.000556338,0.0006616442,0.0006226689,0.0001294567,0.0004589562,0.0003477716,0.0004694115,0.005938406],"category_scores_gemma":[0.0008059001,0.00008525507,0.0005866407,0.0004804742,0.0001595537,0.0002998715,0.0002546731,0.0008538666,0.00177015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002462934,"about_ca_system_score_gemma":0.0004724278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003266901,"about_ca_topic_score_gemma":0.0007085107,"domain_scores_codex":[0.9997386,0.0000627545,0.00003504569,0.00003339026,0.0001009658,0.00002925101],"domain_scores_gemma":[0.9996014,0.0001146952,0.0001286675,0.000009323134,0.0001141698,0.0000317521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001425117,0.0001679025,0.0009898355,0.01259643,0.000370487,0.0003718936,0.00004186112,0.0002586384,0.007231133,0.001531126,0.04846735,0.9265482],"study_design_scores_gemma":[0.001118515,0.003212985,0.01505808,0.01083886,0.001114627,0.00615266,0.0001010604,0.0004223585,0.008111398,0.002236918,0.9515868,0.00004565719],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002363365,0.9896512,0.0003671831,0.001982237,0.0009986671,0.00002684872,0.0001236711,0.00003223706,0.00445456],"genre_scores_gemma":[0.02375165,0.9637992,0.001063299,0.002522541,0.002178233,0.00003743584,0.0003095505,0.00001437002,0.006323736],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005938406,"threshold_uncertainty_score":0.01986599,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06068419422584077,"score_gpt":0.3784755663729056,"score_spread":0.3177913721470649,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}